Diagnostic Development, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, M5G 0A3, Canada.
Informatics Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, M5G 0A3, Canada.
J Ovarian Res. 2018 Apr 4;11(1):27. doi: 10.1186/s13048-018-0399-7.
Ovarian cancer is the leading gynecologic cancer diagnosed in North America and because related symptoms are not disease specific, this often leads to late detection, an advanced disease state, and the need for chemotherapy. Ovarian cancer is frequently sensitive to chemotherapy at diagnosis but rapid development of drug resistance leads to disease progression and ultimately death in the majority of patients.
We have generated paclitaxel resistant ovarian cell lines from their corresponding native cell lines to determine driver mechanisms of drug resistance using gene expression arrays. These paclitaxel resistant ovarian cells demonstrate: (1) Increased IC for paclitaxel and docetaxel (10 to 75-fold) and cross-resistance to anthracyclines (2) Reduced cell apoptosis in the presence of paclitaxel (3) Gene depletion involving mitotic regulators BUB1 mitotic checkpoint serine/threonine kinase, cyclin BI (CCNB1), centromere protein E (CENPE), and centromere protein F (CENPF), and (4) Functional data validating gene depletion among mitotic regulators.
We have generated model systems to explore drug resistance in ovarian cancer, which have revealed a key pathway related to the spindle assembly checkpoint underlying paclitaxel resistance in ovarian cell lines.
卵巢癌是北美地区诊断出的主要妇科癌症,由于相关症状并非特定于该疾病,因此常常导致晚期发现、疾病处于晚期状态,以及需要化疗。卵巢癌在诊断时通常对化疗敏感,但药物耐药性的迅速发展导致疾病进展,最终大多数患者死亡。
我们从相应的天然细胞系中生成了紫杉醇耐药的卵巢细胞系,以使用基因表达谱来确定耐药的驱动机制。这些紫杉醇耐药的卵巢细胞表现出:(1)对紫杉醇和多西紫杉醇的 IC 增加(10 到 75 倍)和对蒽环类药物的交叉耐药性;(2)在紫杉醇存在下细胞凋亡减少;(3)涉及有丝分裂调节剂 BUB1 有丝分裂检查点丝氨酸/苏氨酸激酶、细胞周期蛋白 BI(CCNB1)、着丝粒蛋白 E(CENPE)和着丝粒蛋白 F(CENPF)的基因缺失;(4)验证有丝分裂调节剂中基因缺失的功能数据。
我们已经生成了用于探索卵巢癌耐药性的模型系统,这些系统揭示了与纺锤体组装检查点相关的关键途径,该途径是卵巢细胞系中紫杉醇耐药的基础。